Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

ISTA Pharmaceuticals Receives FDA Approval for BROMDAY™

October 16, 2010 By Bio-Medicine.Org

IRVINE, Calif., Oct. 16 /PRNewswire-FirstCall/ — ISTA
Pharmaceuticals, Inc. (Nasdaq:
ISTA), today announced the U.S. Food and Drug Administration
(FDA) has approved the Company’s supplemental New Drug Application
(sNDA) for BROMDAY™ (bromfenac ophthalmic solution) 0.09% as
a once-daily prescription eye drop for the treatment of
postoperative inflammation and reduction of ocular pain in patients
who have undergone cataract extraction.  ISTA expects to
launch BROMDAY (formerly referred to as XiDay) prior to the end of
2010.    

“BROMDAY is the only once-daily ophthalmic nonsteroidal
anti-inflammatory drug (NSAID) for the treatment of postoperative
inflammation and reduction of ocular pain in patients who have
undergone cataract extraction.  We believe the convenience of
a once-daily eye drop will help with treatment compliance and
benefit patients recovering from cataract surgery,” stated Vicente
Anido, Jr., Ph.D., President and Chief Executive Officer of ISTA.
 “BROMDAY is an important addition to our growing prescription
eye and allergy product portfolio. Within just a few weeks, our
expanded sales force will be ready to promote BROMDAY to U.S.-based
ophthalmologists, along with BEPREVE®, our recently launched
eye drop for the treatment of itching associated with allergic
conjunctivitis.

“Since the BROMDAY approval process required additional clinical
investigations beyond those conducted for the original approval of
XIBROM™ 0.09%, we are seeking a three-year exclusivity period
under the Drug Price Competition and Patent Term Restoration Act,
commonly known as the Hatch-Waxman Act.  BROMDAY represents a
significant step in extending our successful bromfenac-based
product line established when we launched XIBROM, our twice-daily
NSAID for use following cataract surgery, in 2005.  In
addition, we are evaluating a new

‘/>”/>

SOURCE

Related Articles Read More >

TE Connectivity opens global medical device prototyping center in Ireland
Prix Galien USA 2022 nominees
The 24 best medical device innovations of 2022
A portrait of Ellen Roche, MIT School of Engineering associate professor
New implant design prevents scar tissue without drugs, MIT says
UMN artificial blood vessel clinical trial
Minnesota researchers awarded $3.7M grant for artificial, bioengineered blood vessel clinical trial

DeviceTalks Weekly.

August 12, 2022
DTW – Medtronic’s Mauri brings years of patient care to top clinical, regulatory, scientific post
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • Subscribe to Print Magazine
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech